Galen

What Galen does

Galen is a privately owned pharmaceutical sales, marketing and distribution company established in 1968 and headquartered in Craigavon, Northern Ireland. It commercialises a portfolio of 75+ branded generic and specialty pharmaceutical products across multiple therapeutic areas — including emergency pain management (Penthrox/methoxyflurane), gastroenterology (Laxido), medical nutrition for inherited metabolic disorders (PKU EASY, TYR EASY, HCU EASY products), oncology supportive care (GelX Oral Spray, DaunoXome), dermatology and local analgesia (Synera with its proprietary CHADD heat-assisted delivery platform), and respiratory diagnostics (Provocholine). Galen serves healthcare professionals, hospital systems, NHS/HSE and equivalent public reimbursement systems, and patients with metabolic disorders across the UK, Republic of Ireland, Nordics, Germany, the US and through global distributor partners on every continent.

Galen's business model centres on in-licensing, out-licensing, distribution partnerships and selective acquisitions of pharmaceutical assets, layered on top of its own branded generic formulations. Core proprietary technologies include the CHADD (Controlled Heat Assisted Drug Delivery) platform used in the Synera patch and the dual-coating microtab technology that delivers palatable taste and slow-release amino acids in PKU EASY Microtabs. Revenue is generated through direct sales operations in the UK, Ireland and the Nordics (via wholly-owned POA Pharma Scandinavia AB and POA Pharma GmbH subsidiaries), supplemented by licensing royalties, in-licensing of partner products such as Cariban (Italfarmaco), GelX (Sunstar Suisse), Provocholine (Methapharm) and Rapilose OGS (Penlan Healthcare), and out-licensing of its Medical Nutrition range and Laxido worldwide. Pricing is reimbursement-driven rather than transaction-based; most products are prescribed and reimbursed through national healthcare systems.

Galen is the founding member of the Almac Group, a privately held contract development and manufacturing organisation wholly owned by the McClay Foundation. Almac Group employs 6,500+ personnel across 18 facilities globally, providing Galen with vertically integrated development and manufacturing capability that is unusual for a company of Galen's commercial scale. The group is led at Almac level by Alan Armstrong (CEO and Chairman); Galen itself is led by Managing Director and President Dr Dennise Broderick, with Simon Lawrence as VP of Marketing and Medical Nutrition. Galen's growth is driven by a steady cadence of geographic expansion (most recently Germany in 2023 and the Istituto Gentili Nordic deal in 2026), therapeutic-area broadening via in-licensing, and product-line innovation in metabolic disorders, rather than by venture-style rapid scaling.

Name

Galen

Legal name

Galen Limited

Website

https://galen-pharma.com

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

11–50 employees

Short description

Galen is a privately owned Northern Irish pharmaceutical sales and marketing company, established 1968, that in-licenses, out-licenses and distributes 75+ branded generic and specialty medicines across pain management, gastroenterology, metabolic disorders, oncology and respiratory care in the UK, Ireland, Nordics, Germany and the US.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (4242), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

Keywords

• Branded generic pharmaceuticals
• Medical nutrition products
• Emergency pain relief
• Pharmaceutical in-licensing
• Specialty pharma distribution

Headquarters

HQ city

Craigavon

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others

Revenue model

1. Pharmaceutical Product Sales and Marketing: Galen generates revenue through sales and marketing of pharmaceutical products in therapeutic areas including medical nutrition, gastroenterology, pain management, dermatology, respiratory disease, oncology, and emergency medicine. Products are distributed across UK, Republic of Ireland, Nordics, Europe and USA.
2. Licensing and Distribution Partnerships: Revenue generated through licensing agreements where Galen acquires rights to market and sell products in specific territories. This includes in-licensing arrangements where products are acquired from partners like Penlan Healthcare (Rapilose OGS), Methapharm (Provocholine), and Italfarmaco (Cariban), and out-licensing of Galen's Medical Nutrition range and Laxido branded products worldwide.
3. Acquisition-based Growth: Growth through strategic acquisitions of companies and product portfolios. Notable acquisitions include POA Pharma Scandinavia AB (2020) for Nordic expansion, and product acquisitions including Synera (US market), DaunoXome (oncology), GelX Oral Spray, and Provocholine.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Galen is a privately owned pharmaceutical sales and marketing company that develops, in-licenses, and commercializes branded generic and specialty pharmaceutical products. Its portfolio spans 75+ products across pain management, gastroenterology, dermatology, respiratory, oncology, and emergency medicine, including in-house and licensed brands such as Penthrox (methoxyflurane pain relief inhaler), Laxido (osmotic laxative), Synera (heat-assisted topical anesthetic patch), GelX Oral Spray (oral mucositis), Provocholine (asthma diagnosis), and a Medical Nutrition line (PKU EASY, TYR EASY, HCU EASY microtabs and shakes) for inherited metabolic disorders.

Product overview

Galen is a privately owned pharmaceutical sales and marketing company offering a diverse portfolio of pharmaceutical products and medical nutrition therapies. The product portfolio consists of core branded products including Penthrox (emergency pain relief inhaler), in-licensed/acquired brands such as GelX Oral Spray, Provocholine, and Synera, and the Medical Nutrition product line (PKU EASY, TYR EASY, HCU EASY products for metabolic disorders) alongside Laxido (constipation treatment). Galen operates through pharmaceutical partnerships, in-licensing, out-licensing, and acquisitions to commercialize products across the UK, Ireland, Europe, Nordics, and US markets.

Differentiator

Problem solved

Functional benefit

Brands

• Galen Medical Nutrition: Medical nutrition products for dietary management of inborn errors of metabolism including PKU, TYR, HCU, MSUD, and UCD.
• POA Pharma

Products and services

• Penthrox (methoxyflurane) Emergency pain relief inhaler using methoxyflurane for moderate to severe trauma pain in conscious patients, self-administered under trained supervision using a handheld inhaler; licensed for adults and children aged 6+ in the UK. Used by emergency departments, paramedics, and A&E clinicians.
• Laxido Branded generic range of osmotic laxatives (Laxido Orange and Laxido Paediatric Plain) containing macrogol 3350 plus electrolytes for treatment of chronic constipation and faecal impaction; UK's market-leading osmotic laxative with the same qualitative and quantitative composition as MOVICOL.
• Medical Nutrition Product Line (PKU EASY Microtabs, PKU EASY Shake & Go, TYR EASY Shake & Go, TYR EASY Tablets, HCU EASY Tablets) Foods for special medical purposes for the dietary management of inborn errors of metabolism including Phenylketonuria (PKU), Tyrosinaemia (TYR), Homocystinuria (HCU), Maple Syrup Urine Disease (MSUD), and Urea Cycle Disorders (UCD). Includes PKU EASY Microtabs with proprietary dual-coating technology for palatable slow-release amino acid delivery, plus shake and tablet formats across the range.
• Synera (lidocaine/tetracaine topical patch) Topical patch combining local anaesthetics lidocaine and tetracaine with proprietary CHADD (Controlled Heat Assisted Drug Delivery) heat technology for local dermal analgesia during superficial venous access and dermatological procedures. Distributed by Galen US Inc.
• GelX Oral Spray Oral spray product designed to treat Oral Mucositis (OM), a painful inflammation of the lining of the mouth and throat often caused by radiation and chemotherapy cancer treatments; distributed exclusively in UK and Ireland by Galen under partnership with Sunstar Suisse S.A. for hospital use by clinicians.
• Provocholine (methacholine chloride 100mg Powder for nebuliser solution) Methacholine chloride 100mg Powder for nebuliser solution used by healthcare specialists to detect bronchial airway hyperreactivity, assisting in the diagnosis of asthma in patients aged 17 and over. Acquired for exclusive UK distribution from Methapharm Specialty Pharmaceuticals of Canada.
• Rapilose OGS (Oral Glucose Solution) Ready-to-use oral glucose solution providing 75g anhydrous glucose per 300ml pouch for the dietary management of disease-related malnutrition and malabsorption states; in-licensed from Penlan Healthcare Limited for distribution in Germany via POA Pharma.

Quantifiable outcome

• 71 minutes average time saved per patient using Penthrox compared to standard care in A&E departments
• +3 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

19 partnerships are on record, tiered core and minor.

• Istituto GentilicoreChannel Partner/ Reseller/ Distributor · 16 April 2026New licensing partnership where POA Pharma Scandinavia AB (Galen subsidiary) assumes exclusive distribution responsibilities for Istituto Gentili products across Denmark, Finland and Norway. Strengthens Galen's Nordic portfolio.
• ItalfarmacocoreChannel Partner/ Reseller/ Distributor · 30 July 2024Exclusive licensing agreement for distribution of Cariban (doxylamine/pyridoxine) in Ireland for treatment of Nausea and Vomiting in Pregnancy (NVP). Women in Ireland can now access fully reimbursed treatment through Drugs Payment Scheme or Medical Card.
• Penlan Healthcare LimitedcoreChannel Partner/ Reseller/ Distributor · 19 September 2022Exclusive in-licensing agreement for Rapilose Oral Glucose Solution (OGS). POA Pharma entered German market via this agreement. Rapilose OGS is for dietary management of disease-related malnutrition and malabsorption states.
• Sunstar Suisse S.A.coreChannel Partner/ Reseller/ Distributor · 21 April 2022Partnership for exclusive distribution and commercialization of GelX Oral Spray in the United Kingdom and Ireland. GelX treats Oral Mucositis (OM), a painful inflammation caused by cancer radiation and chemotherapy treatments.
• Methapharm Specialty PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 11 April 2022Acquired rights to distribute Provocholine (methacholine chloride 100mg) in the United Kingdom. Provocholine is used to detect bronchial airway hyperreactivity to assist in asthma diagnosis. Manufactured by Methapharm of Canada.
• Nexus Patient ServicescoreChannel Partner/ Reseller/ Distributor · 15 October 2021Nexus Patient Services became sole distributor for Galen Medical Nutrition in the United States. This agreement allows Nexus to provide continued access to Galen's high quality medical nutrition products for US patients with metabolic disorders.
• POA Pharma Scandinavia ABcoreOthers · 1 January 2020Galen acquired POA Pharma Scandinavia AB in January 2020 for multi-million pounds. This acquisition was a major step forward for Galen, allowing expansion into the Nordic region (Denmark, Finland, Norway, Sweden) and broadening the product range. POA Pharma brought expertise in acute care, ENT, and medical nutrition.
• Nuvo Research Inc.coreChannel Partner/ Reseller/ Distributor · 11 July 2013Product acquisition and license agreement for exclusive rights to market and sell Synera (lidocaine/tetracaine topical patch) in the United States. Upfront payment of US$4.5 million with 10% royalties on net sales and milestone payments up to US$10 million.
• Gilead Sciences, Inc.coreChannel Partner/ Reseller/ Distributor · 1 January 2012Acquired chemotherapy agent DaunoXome (daunorubicin citrate liposome injection) from Gilead Sciences. Galen markets DaunoXome in the US as part of initial entry into United States market.
• Almeda Pharmaceuticals AGminorChannel Partner/ Reseller/ DistributorExclusive licensing partnership. CEO Ala Tocarciuc stated commitment to improving access to medicines and treatments for patients.
• College of ParamedicscoreGTM or Marketing PartnerPartnership for Dr John Hinds Scholarship Award, now in seventh year. Supports pre-hospital emergency care professionals with fully funded ATACC course placements and recognition. Also partnership for Paramedic Science Award with Ulster University.
• ATACC GroupcoreGTM or Marketing PartnerPartnership for Dr John Hinds Scholarship Award providing the renowned Advanced Trauma and Critical Care (ATACC) three-day course. ATACC Group delivers medical education courses and mass casualty simulation worldwide.
• Ulster UniversitycoreGTM or Marketing PartnerThree-year partnership for Paramedic Science Award for Extraordinary Peer Support recognizing students demonstrating exceptional peer support in BSc Hons Paramedic Science programme at Ulster University Derry/Londonderry campus.
• Almac GroupcoreStrategic or Co-development PartnerGalen is the founding member of Almac Group - established contract development and manufacturing organization providing integrated services across drug development lifecycle. Group is wholly owned by McClay Foundation with aim to advance human health. Almac employs 6,500+ personnel across 18 facilities globally.
• Global Emergency Care Skills (GECS)minorGTM or Marketing PartnerIrish voluntary non-profit organization providing trauma skills training to doctors, nurses and clinical officers in African hospitals. Galen supports this charity focusing on sepsis and trauma care training.
• The Swallows Head and Neck Cancer CharityminorGTM or Marketing PartnerGalen made £3,000 donation to The Swallows Charity benefiting from Galen's attendance at Head and Neck Cancer Conference. Supports head and neck cancer patients and professionals.
• POA Pharma GmbHcoreOthersWholly-owned subsidiary founded in 2023 for German market operations. Represents Galen's expansion into German pharmaceutical market following Nordic success with POA Pharma Scandinavia AB.
• Bora Health InccoreChannel Partner/ Reseller/ DistributorTaiwan-based company. Exclusive licensing agreement for Microtabs Plus - expanding Galen's medical nutrition portfolio for metabolic disorders globally.
• SalvatcoreChannel Partner/ Reseller/ DistributorPartnership with POA Pharma Scandinavia AB expanding Nordic ENT (Ear, Nose, Throat) portfolio through exclusive licensing agreement for Galen products in the Nordic region.

Scale indicators12 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Shire (now part of Takeda): Specialty pharma with rare-disease, GI and internal medicine franchises built via in-licensing, acquired strongly overlaps with Galen's medical nutrition and rare metabolic disorder portfolio approach.
• Recordati: European specialty pharma with rare-disease and gastroenterology franchises built through licensing and acquisitions - directly comparable commercial model and therapeutic-area adjacency to Galen.
• Aspen Pharmacare: Specialty and branded-generic pharma operating globally through regional acquisitions and licensing - parallels Galen's regional entry-and-build approach into Nordics and Germany.
• Stada Arzneimittel: Large European generics and branded specialty player with extensive in-licensing and channel partnerships, comparable in go-to-market and geographic spread to Galen's licensing-led model.

Direct peers

• Endo International (now Paratek-era Endo): Specialty branded pharma with meaningful pain franchise (including topical anesthetics) and a heavy reliance on in-licensed/acquired specialty assets - similar product-overlap with Galen's pain and emergency medicine portfolio.
• Almirall: European specialty pharma focused on dermatology and gastrointestinal niches with in-licensing as a core growth lever - comparable therapeutic-area focus and licensing-driven commercial model.
• Mallinckrodt Pharmaceuticals: US/EU specialty pharma with branded hospital products including pain management - directly comparable to Galen's portfolio approach across pain, oncology supportive care and hospital-distributed niche therapies.
• Norgine: European specialty pharma whose MOVICOL (macrogol) is the direct competitor to Galen's Laxido in UK/GI; comparable as a European-focused, branded prescription GI specialist.
• ADVANZ PHARMA: Specialty branded and branded-generic pharma company focused on Europe, Canada and Australia, built through acquisitions and in/out-licensing - closely aligned with Galen's acquisition + licensing + commercialization model in therapeutic niches.

Regional players

• Lundbeck: Danish-headquartered specialty pharma with strong neurology and Nordic distribution presence - comparable Nordic operating geography and specialty-pharma distribution model to Galen/POA Pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galen